Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

apatinib 25Cisplatin 19Capecitabine 17Irinotecan 16Cyclophosphamide 16fludarabine 14Radiotherapy 12Oxaliplatin 12Drug Therapy 12camrelizumab 11Paclitaxel 11S 1 (combination) 10Docetaxel 10Carboplatin 10Fluorouracil 9Blood Specimen Collection 9Bevacizumab 9Nivolumab 8tislelizumab 7Radiation 7Pemetrexed 7Gemcitabine 7Erlotinib Hydrochloride 7Surgical Procedures, Operative 6Neoadjuvant Therapy 6Albumin-Bound Paclitaxel 6toripalimab 5anlotinib 5XELOX 5Tamoxifen 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × ivarmacitinib × Clear all
NCT05900089 2023-06-12

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Henan Cancer Hospital

Phase 1 Unknown
30 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡